Syra Health CORP 8-K filings

Syra Health announced robust financial results for Q2 2026, showcasing a 23% revenue increase and sustained profitability.

Syra Health Corp. announced the results of its Annual Meeting of Stockholders held on July 23, 2026, detailing director elections, auditor ratification, and equity incentive plan amendments.

Syra Health announced its first profitable quarter in Q1 2026, with net income of $241,000, driven by revenue growth and margin expansion.

Syra Health Corp. announced significant improvements in its FY2025 financial results, including a 157% growth in population health revenue and a 76% reduction in net loss, with a target to achieve profitability by year-end 2026.

Syra Health Corp. announced the appointment of Gregory R. Alexander, a seasoned healthcare executive and former U.S. Marine, as its new Chief Executive Officer, effective January 5, 2026.

Syra Health Corp. has amended its Certificate of Incorporation to modify the transferability and conversion rules for its Class B Common Stock, effective November 18, 2025.

Syra Health Corp. stockholders approved all five director nominees, ratified its auditor, and passed two amendments related to Class B common stock at its Annual Meeting.

Syra Health reports improved gross margins and reduced net loss in Q3 2025, driven by Population Health growth and cost management, despite a revenue decline due to federal spending cuts.

Syra Health Corp. announced the appointment of Radhika Mereddy to its Board of Directors, effective August 13, 2025.

Syra Health Corp. announced significant financial improvements in Q2 2025, driven by population health growth and cost reductions, moving closer to profitability despite government spending uncertainties.

Deepika Vuppalanchi has resigned from the Board of Directors of Syra Health Corp. for personal reasons, effective July 28, 2025, while retaining her role as Chief Executive Officer.

Syra Health Corp. announced the termination of its CEO, Deepika Vuppalanchi, for cause, and the immediate appointment of CFO and COO Priya Prasad as interim CEO.

Syra Health Corp. announces the commencement of a national search for a new CEO as part of a strategic succession plan, with current CEO Dr. Deepika Vuppalanchi to serve as interim.

Syra Health reports a 6% increase in first-quarter revenue to $1.9 million, driven by substantial growth in its Population Health segment and improved gross margins.

Andrew Dahlem resigned from Syra Health Corp.'s Board of Directors on April 25, 2025, for personal reasons.

Syra Health Corp. announces the appointment of Andrew Dahlem, a current director, as the new Chairman of the Board, effective April 7, 2025.

Syra Health Corp. announces a 45% year-over-year revenue increase to $8.0 million for 2024, fueled by significant growth in its Population Health segment and a focus on cost efficiencies.

Syra Health Corp. reported the passing of its Executive Chairman and President, Sandeep Allam, on January 15, 2025.

Syra Health Corp. has regained compliance with Nasdaq listing rules after reporting stockholders' equity of $3.33 million as of September 30, 2024.

Syra Health announced a 42% year-over-year revenue increase and a significant reduction in net loss for the third quarter of 2024, driven by growth in population health and healthcare workforce services.

Syra Health Corp. has been notified by Nasdaq that its stock price has fallen below the minimum $1.00 requirement for continued listing.

Syra Health Corp. received a notice from Nasdaq for not meeting the minimum stockholders' equity requirement, while also projecting a revenue growth of 36%-73% for 2024.

Syra Health announced a 101% increase in revenue for the second quarter of 2024, driven by growth in its Population Health and Healthcare Workforce business units.

Syra Health Corp. held its Annual Meeting of Stockholders on June 18, 2024, where all director nominees were elected and the appointment of the independent auditor was ratified.

Syra Health announced a 47% year-over-year revenue increase in the first quarter of 2024, driven by significant growth in its Population Health business unit.

Syra Health Corp. has appointed its Chief Operating Officer and Chief Financial Officer, Priya Prasad, to its Board of Directors, effective March 27, 2024.

Syra Health announced its 2023 financial results, showing a slight revenue decrease year-over-year but significant growth in key business units and a positive outlook for 2024 with projected revenue growth between 64% and 100%.